Aptevo Therapeutics Inc. cash flow statement

In fiscal 2022, Aptevo Therapeutics Inc.'s operations generated −$21.0m of cash; it spent $29,000 on capital projects, leaving free cash flow of −$21.1m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Aptevo Therapeutics Inc.: cash flow statement, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022
Cash from operations	−49	−37	−42	−51	−42	−29	−22	−21
Depreciation and amortisation	3	3	3	2	2	1	1	1
Stock-based pay	1	4	5	2	2	1	2	2
Capital spending	2	3	1	1	0	0	1	0
Free cash flow	−50	−39	−43	−52	−43	−29	−22	−21
Free cash flow after stock pay	−51	−43	−48	−55	−44	−31	−24	−23
Shares issued	—	—	0	1	—	—	10	7

US$ thousands unless shown otherwise. Fiscal quarters.

Aptevo Therapeutics Inc.: cash flow statement, quarterly
Quarter	2021 Q1Mar 2021	2021 Q2Jun 2021	2021 Q3Sept 2021	2021 Q4Dec 2021	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022
Cash from operations	−7,504	−5,053	−5,242	−3,880	−5,117	−3,070	−6,896	−5,939
Depreciation and amortisation	294	299	295	256	242	276	222	161
Stock-based pay	574	572	319	178	601	484	359	357
Capital spending	191	391	13	118	—	—	4	0
Free cash flow	−7,695	−5,444	−5,255	−3,998	—	—	−6,900	−5,939
Free cash flow after stock pay	−8,269	−6,016	−5,574	−4,176	—	—	−7,259	−6,296
Shares issued	—	10	0	0	—	—	0	6,498

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aptevo Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aptevo Therapeutics Inc.